These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 25394036)

  • 1. Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study.
    O'Connor J; Smith C; Lampe F; Johnson M; Sabin C; Phillips A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19527. PubMed ID: 25394036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
    O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
    AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.
    O'Connor J; Smith C; Lampe FC; Johnson MA; Chadwick DR; Nelson M; Dunn D; Winston A; Post FA; Sabin C; Phillips AN;
    Lancet HIV; 2017 Jul; 4(7):e295-e302. PubMed ID: 28479492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
    Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
    Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcome of first-line antiretroviral therapy among HIV-1 vertically-infected children in Hanoi, Vietnam.
    Pham HV; Ishizaki A; Nguyen LV; Phan CT; Phung TT; Takemoto K; Pham AN; Bi X; Khu DT; Ichimura H
    Int J STD AIDS; 2015 Oct; 26(11):821-30. PubMed ID: 25332224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Kay CN; Taka N; Awasom C; Metzner K; Jan vL; Feldt T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19615. PubMed ID: 25394119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early HIV viral load determination after initiating first-line antiretroviral therapy for indentifying patients with high risk of developing virological failure: data from a cohort study in a resource-limited setting.
    Alvarez-Uria G; Naik PK; Pakam R; Midde M
    Trop Med Int Health; 2012 Sep; 17(9):1152-5. PubMed ID: 22487689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting.
    d'Arminio Monforte A; Gianotti N; Cozzi-Lepri A; Pinnetti C; Andreoni M; di Perri G; Galli M; Poli A; Costantini A; Orofino G; Maggiolo F; Mazzarello G; Celesia BM; Luciani F; Lazzarin A; Sighinolfi L; Rizzardini G; Bonfanti P; Perno CF; Antinori A;
    Antivir Ther; 2014; 19(3):319-24. PubMed ID: 24036891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everything counts - a method to determine viral suppression among people living with HIV using longitudinal data for the HIV care continuum - results of two large, German, multi-center real-life cohort studies over 20 years (1999-2018).
    Schmidt D; Kollan C; Stoll M; Hamouda O; Bremer V; Kurth T; Bartmeyer B; ;
    BMC Public Health; 2021 Jan; 21(1):200. PubMed ID: 33482773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
    Seang S; Fourati S; Keita Y; Blanc C; Tubiana R; Schneider L; Valantin MA; Caby F; Calin R; Lambert-Niclot S; Marcelin AG; Calvez V; Costagliola D; Katlama C
    J Antimicrob Chemother; 2014 Dec; 69(12):3356-9. PubMed ID: 25056835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Galli M; Caramello P; Abrescia N; Mussini C; Monno L; Monforte Ad
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19769. PubMed ID: 25397513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with HIV RNA viral loads in ART-naïve patients: implications for treatment as prevention in concentrated epidemics.
    Rangarajan S; Colby DJ; Truong GL; Huu HN; Thu VT; Quoc BL; Broh TP; Tri DT; Giang DD; Chen M; Zeng Y; West G
    J Virus Erad; 2016 Jan; 2(1):36-42. PubMed ID: 27482434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1.
    Labhardt ND; Bader J; Ramoeletsi M; Kamele M; Lejone TI; Cheleboi M; Motlatsi MM; Ehmer J; Faturyiele O; Puga D; Klimkait T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19666. PubMed ID: 25397416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi.
    Luebbert J; Tweya H; Phiri S; Chaweza T; Mwafilaso J; Hosseinipour MC; Ramroth H; Schnitzler P; Neuhann F
    Clin Infect Dis; 2012 Aug; 55(3):441-8. PubMed ID: 22573849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.